- Conditions
- Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms, Ovarian Cancer, Ovarian Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Appendiceal Cancer, Appendiceal Neoplasms, Cholangiocarcinoma, Breast Cancer
- Interventions
- Paclitaxel, Nilotinib, ECG, CT Scan CAP, Laparoscopy, Peritoneal biopsies + ascites washings
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–42
of 18
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Obscure Gastrointestinal Bleeding
- Interventions
- Not listed
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV-2 Infection, SARS-CoV-2 Acute Respiratory Disease, COVID-19
- Interventions
- Famotidine, Celecoxib, Placebo
- Drug · Other
- Lead sponsor
- Leidos Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Acute Ischemic Stroke
- Interventions
- Transcranial Direct Current Stimulation (tDCS)
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glomerulosclerosis, Focal
- Interventions
- Cyclosporin, MMF and Dexamethasone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 2 Years to 40 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Endometrial Cancer, ARID1A Gene Mutation, Recurrent Endometrial Carcinoma
- Interventions
- Avelumab, M1774
- Drug
- Lead sponsor
- Panagiotis Konstantinopoulos, MD, PhD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- HNSCC
- Interventions
- Cesium-131, Pembrolizumab
- Device · Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Philadelphia, Pennsylvania
- Conditions
- Healthy, Opioid Use Disorder
- Interventions
- Carfentanil, C-11, Naloxone, Loperamide Hydrochloride
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alcohol-induced Cue-craving, Alcohol Sensitivity
- Interventions
- Placebo Comparator, Active Comparator: Atomoxetine, Placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Charlottesville/ Richmond, Virginia
- Conditions
- Opioid Use Disorder
- Interventions
- [11C]-PHNO, Calcitriol, Placebo Control, PET Scan
- Drug · Dietary Supplement · Other + 1 more
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
- Interventions
- Rituximab, Etoposide, Copanlisib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, ECHO, EKG, MRI Brain, 18F-FDG - PET, CT Scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP)
- Biological · Drug · Diagnostic Test + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Thyroid Cancer
- Interventions
- Iodine-124, Positron Emission Tomography (PET)/Computerized tomography (CT)
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pancreatic Acinar Cell Carcinoma
- Interventions
- Olaparib, ECG, CT CAP, Tumor Biopsy
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mantle Cell Lymphoma, Lymphoma
- Interventions
- Bendamustine, Rituximab, Cytarabine, Zanubrutinib, Sonrotoclax
- Drug
- Lead sponsor
- Christine Ryan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Boston, Massachusetts • Rochester, Minnesota + 2 more
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03, Computed Tomography, Zanzalintinib
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Anal Chlamydia Infection
- Interventions
- Azithromycin, Doxycycline, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Seattle, Washington
- Conditions
- Suicidal Ideation
- Interventions
- Home-based transcranial direct current stimulation (tDCS), Sham home-based transcranial direct current stimulation (tDCS)
- Device
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Hodgkin Lymphoma
- Interventions
- Brentuximab vedotin (SGN-35), Doxorubicin HCL, Vinblastine Sulfate, Dacarbazine, Involved-Site Radiation Therapy (ISRT), Interim PET, consolidation volume RT (CVRT)
- Drug · Radiation · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 10
- States / cities
- Duarte, California • Stanford, California • Basking Ridge, New Jersey + 7 more